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Abstract
Background: Increasing evidences indicate that an unbalance between tryptases and their endogenous inhibitors,
leading to an increased proteolytic activity, is implicated in the pathophysiology of rheumatoid arthritis. The aim of
the present study was to evaluate the impact of tryptase inhibition on experimental arthritis.
Methods: Analysis of gene expression and regulation in the mouse knee joint was performed by RT-qPCR and in
situ hybridization. Arthritis was induced in male C57BL/6 mice with mBSA/IL-1β. Tryptase was inhibited by
two approaches: a lentivirus-mediated heterologous expression of the human endogenous tryptase inhibitor,
sperm-associated antigen 11B isoform C (hSPAG11B/C), or a chronic treatment with the synthetic tryptase
inhibitor APC366. Several inflammatory parameters were evaluated, such as oedema formation, histopathology,
production of IL-1β, -6, -17A and CXCL1/KC, myeloperoxidase and tryptase-like activities.
Results: Spag11c was constitutively expressed in chondrocytes and cells from the synovial membrane in mice,
but its expression did not change 7 days after the induction of arthritis, while tryptase expression and activity
were upregulated. The intra-articular transduction of animals with the lentivirus phSPAG11B/C or the treatment
with APC366 inhibited the increase of tryptase-like activity, the late phase of oedema formation, the production
of IL-6 and CXCL1/KC. In contrast, neutrophil infiltration, degeneration of hyaline cartilage and erosion of
subchondral bone were not affected.
Conclusions: Tryptase inhibition was effective in inhibiting some inflammatory parameters associated to
mBSA/IL-1β-induced arthritis, notably late phase oedema formation and IL-6 production, but not neutrophil
infiltration and joint degeneration. These results suggest that the therapeutic application of tryptase inhibitors
to rheumatoid arthritis would be restrained to palliative care, but not as disease-modifying drugs. Finally, this
study highlighted lentivirus-based gene delivery as an instrumental tool to study the relevance of target genes
in synovial joint physiology and disease.
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Background
Rheumatoid arthritis (RA) is a multifactorial auto-
immune disease affecting nearly 1% of the world popula-
tion, whose pathophysiology involves multiple cellular
and molecular processes underlying synovial inflamma-
tion, joint swelling and pain, and ultimately destruction
of articular cartilage and subchondral bone [1]. One of
the histopathological hallmarks of RA is a marked in-
crease of mast cell infiltration within the synovium [2–4].
Initial indications on how mast cells could be implicated
in the pathophysiology of RA came from studies demon-
strating that mast cell-deficient mice, bearing mutations
in the c-Kit signalling pathway, developed less severe
forms of antigen- or autoantibody-induced arthritis [5–7].
Recent studies, based on more selective strategies for mast
cell deficiency in mice, supported a role for these cells in
this disease, notably in the pre-clinical phase of T cell-
driven antigen-induced arthritis models [8, 9].
The trypsin-like serine protease isoenzymes tryptase-
α/β1 (TPSAB1) and -β2 (TPSB2), commonly referred as
tryptases, are amongst the most abundant proteases
stored within mast cell secretory granules and are
pivotal pro-inflammatory mediators in the pathophysi-
ology of allergic and inflammatory diseases [10, 11]. For
instance, genetically modified mice lacking mast cell
protease-6 and -7 (Mcpt-6 and Mcpt-7), have reduced
inflammatory and degenerative parameters associated
to experimental arthritis [12, 13]. Indeed, tryptases are
emerging as potential therapeutic targets to treat
chronic inflammatory diseases. However, these enzymes
are stored and secreted as tetramers, wherein the active
site is sheltered within the oligomeric catalytic pocket.
While this tetrameric assembly conveys substrate speci-
ficity, it renders this enzymatic complex resistant to
most of the endogenous circulating anti-peptidases,
such as α1-anti-trypsin and α2-macroglobulin [14, 15].
Additionally, this structural arrangement challenges
the design of highly selective and orally bioavailable
inhibitors [16].
Interestingly, the N-terminal region of the recombinant
human β-defensin sperm-associated antigen 11B isoform
D (hSPAG11B/D), which is conserved in hSPAG11B/C,
has been reported in vitro as a potent inhibitor of
tryptase-β1 [17]. β-defensins are anti-microbial proteins
primarily associated with host defense [18, 19]. Moreover,
increasing evidences suggest that β-defensins have immu-
nomodulatory properties and a variety of other non-
immunological activities [20, 21]. Indeed, we recently re-
ported that the rat β-defensin SPAG11C, the ortholog of
the human SPAG11B isoform C, hSPAG11B/C, is
expressed in articular chondrocytes during the male rat
embryonic development [22]. However, their potential
contribution in controlling inflammatory conditions such
as RA remains elusive.
Herein, we hypothesized that an unbalance between
tryptases and their endogenous inhibitors, leading to an
increased proteolytic activity, is implicated in the patho-
physiology of RA. Therefore, we sought to investigate
whether this novel endogenous tryptase inhibitor,
SPAG11C, is expressed and under regulation during ex-
perimentally induced arthritis in the adult mouse knee
joint. Considering evidence from studies employing
genetically engineered tryptase-deficient mice [12, 13],
we also evaluated the potential of tryptase inhibition as
a therapeutic alternative for the management of RA.
We assessed the impact of two distinct approaches for tryp-
tase inhibition on several inflammatory parameters associ-
ated to methylated bovine serum albumin/interleukin-1β
(mBSA/IL-1β)-induced arthritis: the lentivirus-mediated
heterologous expression of hSPAG11B/C gene product
within the adult mouse knee joint, as well as the mouse
intra-articular treatment with the synthetic tryptase inhibi-
tor APC366 [23].
Methods
Cloning of the hSPAG11B/C coding sequence into
pWPXLd-IG
The lentivirus vector pWPXLd (Addgene, Cambridge,
MA, USA) was modified by the replacement of the en-
hanced green fluorescent protein (eGFP) coding sequence
by a PCR fragment harboring the internal ribosomal entry
site (IRES)-eGFP cassette from pIRES-eGFP vector (Clon-
tech, Mountain View, CA, USA), thus generating the
bicistronic vector pWPXLd-IG. Additionally, an adaptor
oligonucleotide was inserted between PmeI and BamHI in
order to increase the restriction endonuclease repertoire
in the multiple cloning site (MluI, SgfI, PvuI, RsrII and
BSu36I).
The coding sequence of hSPAG11B/C was obtained
from human testis and epididymis total ribonucleic acid
(RNA) reverse transcribed using ThermoScript RT-PCR
System (Thermo Fisher Scientific, Waltham, MA, USA)
followed by a PCR performed with the Phusion High-Fi-
delity DNA Polymerase Kit (NEB, Ipswich, MA, USA) and
respective oligonucleotide pair as follows: forward: 5‘-
AGTTTAAACGCCACCATGAGGCAACGA-3’; reverse
5’-CTATGGATCCTTAATGTAAACAGCAGGCGTC-3’.
QIAquick purified (Qiagen, GmbH, Hilden, Germany)
PCR products were A+ tailed (Thermo Fisher Scientific)
and ligated into the transfer plasmid pGEM-T Easy
System I (Promega, Madison, WI, USA), transformed
into TOP10 competent cells (Thermo Fisher Scientific),
amplified and purified using QIAprep Spin Miniprep Kit
(Qiagen). Inserts of interest were released from positive
pGEM-T plasmids by double digestion with the endonu-
cleases PmeI and BamHI (NEB), fractioned by prepara-
tive agarose gel electrophoresis, purified with the
QIAquick Gel Extraction Kit (Qiagen) and ligated into
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linearized and dephosphorylated (NEB) pWPXLd-IG
lentivirus vectors using a 1:3 vector to insert ratio with
the T4 DNA Ligase Kit (Thermo Fisher Scientific). For
simplification reasons, the resulting vector pWPXLd-
hSPAG11B/C-IG will be referred as phSPAG11B/C. NEB
5-alpha electrocompetent E. coli were transformed with
the ligation reaction mix using a MicroPulser Electro-
porator (Bio-Rad, Hercules, CA, USA). Clones were
amplified and purified and subcloning efficiency was
confirmed by automatic DNA sequencing. Lentivirus
transfer and the structural vectors pMD2.G and psPAX.2
(Addgene plasmids #12260 and #12259, both provided
by D. Trono) were amplified and purified using the
NucleoBond® Xtra Maxi Plus EF Kit (Macherey-Nagel,
GmbH, Düren, Germany).
Lentivirus production and titration
HEK293T/17 cells were cultured according to supplier’s
recommendations (ATCC, Manassas, VA, USA). Cells
(1.7 × 107 per plate) were seeded into 10-cell culture
flasks (175 cm2) containing 30 mL of DMEM (Gibco,
Carlsbad, CA, USA) and then incubated at 37 °C 5%
CO2. The next day, cells were transfected with a mixture
of structural (146 μg of psPAX2 and 79 μg of pMD2.G)
and transfer vectors (225 μg of pWPXLd-IG or
phSPAG11B/C), by using the transfection reagent Gene-
Juice (EMD Millipore, Billerica, MA, USA). Cells were
incubated overnight at 37 °C 5% CO2, then the medium
was replaced by 18 mL of OptiMEM (Gibco). Cell cul-
ture supernatants were harvested 24 and 48 h later. Each
supernatant was cleared by centrifugation and filtration
with a 0.45 μm syringe filter and stored at 4 °C. The
virus harvests from 24 and 48 h were pooled and layered
onto 5 mL of a 20% sucrose solution in Dulbecco's
phosphate-buffered saline (DPBS) containing Ca2+ and
Mg2+ and then centrifuged at 106,750 × g for 2 h. The
pellets were solubilized in DPBS, the samples were frac-
tioned into 20 μL aliquots and stored at -80 °C until use.
For the biological titration of the lentiviruses, HEK293T/
17 cells (4 × 104 per well) were seeded into a 24-well plate
containing coverslips. The next day, cells were transduced
with a serial dilution of lentivirus (10−3 to 10−8) and culti-
vated for an additional 72 to 92 h. Cells were fixed with
4% buffered formalin and processed for immunofluores-
cence, as described below. The protocol presented above
is the final standardization of several attempts to optimize
the production of recombinant lentivirus at high titers for
in vivo use.
Animals
Male C57BL/6 mice (N = 127, 8–10 weeks old, weighting
from 22.5–27.3 g), which naturally lack functional Mcpt-
7, were from Institute of Pharmacology and Molecular
Biology (INFAR) animal facility (Universidade Federal de
São Paulo – Escola Paulista de Medicina, UNIFESP-EPM,
São Paulo, Brazil) and from Janvier Labs (Le Genest-Saint-
Isle, France). Mice were housed in groups of up to five
animals per cage with access to standard food and water
ad libitum, and maintained in level 2 biosafety installations
under a 12/12 h light/dark cycle and controlled room
temperature (22 ± 1 °C). All invasive or stressful proce-
dures were performed in animals under anaesthesia, either
inhalatory isoflurane 1.5% v/v in oxygen or intraperitoneal
ketamine (80 mg/kg and xylazine 20 mg/kg, respectively).
Induction and analysis of experimental arthritis
Animals were submitted to methylated bovine serum al-
bumin/interleukin-1β (mBSA/IL-1β)-induced arthritis,
as previously described [12]. Briefly, arthritis was in-
duced by one intra-articular injection in the right knee
joint with 10 μL of mBSA (Sigma-Aldrich, St. Louis,
MO, USA) at 20 mg/mL in vehicle (PBS; phosphate-
buffered saline), followed by three subcutaneous daily
injections in the ipsilateral rear footpad with 250 ng of
recombinant human interleukin 1β (rhIL-1β; Peprotech,
Rocky Hill, NJ, USA) diluted in 20 μL of vehicle (0.9%
sodium hydrochloride (NaCl) solution with 0.5% normal
C57BL/6 mouse serum). Animals from the control group
were submitted to the same procedures, but injected
with the respective vehicle solutions. Oedema formation
was monitored by measurements (triplicates) of the
medio-lateral knee joint diameter by using a specially
designed spring-loaded calliper (model #C1X018; Kroe-
plin, GmbH, Schlüchtern, Germany) on days 0, 1, 2, 5
and 7. Animals were sacrificed at the peak of disease,
7 days after the induction of arthritis [24]. The knee
joint samples were harvested and processed accordingly
to the downstream applications to be performed. For
histopathological analysis, the knee joints were fixed in
4% buffered formaldehyde, decalcified and embedded in
paraffin. Medial sections with 5 μm thickness were ob-
tained and submitted to haematoxylin and eosin (H&E)
or safranin O staining. The severity of arthritis was
scored by observers, single blinded to the experimental
groups, by using a semi-quantitative scale based on a
previously established method [12, 24, 25]. Briefly, the
severity of arthritis in coded slides was graded from 0
(normal) to 5 (severe) for five components that com-
prised joint space exudate, synovitis, pannus formation,
cartilage degradation and bone erosion. Likewise, joint
space exudate was identified as leukocytes, either scat-
tered or in aggregates within the joint space. Synovitis
was defined as hyperplasia of the synovial membrane
due to the proliferation of lining layer fibroblast-like
synoviocytes as well as to the infiltration of polymorph
and mononuclear leukocytes. Pannus formation was de-
fined as hypertrophic synovial tissue forming tight junc-
tions with articular surfaces. The extent of cartilage and
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bone erosion was evaluated separately on both condylar
surfaces. Scoring was based on the loss of cartilage
matrix, disruption and loss of cartilage surface, and the
extent and depth of subchondral bone erosion. The aver-
age score for two sections analysed from each joint was
calculated for each component, then the mean values
from the five components was summed, giving an over-
all mean histopathological severity score for each joint
(maximum possible score of 25).
Lentivirus-mediated heterologous expression of
hSPAG11B/C
Animals were submitted to an intra-articular injection
into the right knee joint with 20 μL of 2 × 106-7 trans-
duction units (TU) per joint of pWPXLd-IG or
phSPAG11B/C. Arthritis was induced 7 days later, as de-
scribed above. Seven days after the induction of arthritis,
the animals were sacrificed; the knee joints were har-
vested and processed for histopathological analysis as
described above. In other sets of experiments, 7 days
after the induction of arthritis, the knee joint was
washed twice with 25 μL of sterile saline, which was
pooled and then centrifuged at 3000 × g for 5 min at
4 °C. The resulting cell pellets and supernatants were
stored separately at -80 °C until required for down-
stream experiments. Additionally, the knee joint was
harvested and stored at -80 °C. As a control procedure for
intra-articular lentivirus injection, in every experimental
set, one group of animals was injected with the same
volume of lentivirus vehicle (PBS), 7 days prior to the
induction of arthritis.
Intra-articular administration of APC366
Mice were treated by intra-articular injections with the
synthetic tryptase inhibitor APC366 (10 μL of 10 or
100 μM; Ki = 7.1 μM) or its vehicle (DMSO 0.1%) 1 h
before the induction of arthritis, which were repeated
every other day (days 2, 4 and 6). Oedema formation
was monitored as described above. The animals were
killed 7 days later and both the synovial fluid and knee
joints were harvested for downstream assays, as de-
scribed above.
Reverse transcription, end-point and semi-quantitative
PCR
Total RNA was extracted from knee joints using the
RNeasy Mini Plus Kit (Qiagen) and 1 μg was reverse
transcribed with the ThermoScript RT-PCR System and
Oligo d(T), according to manufacturer’s instructions
(Thermo Fisher Scientific). For end-point PCR, comple-
mentary deoxyribonucleic acid (cDNA) was amplified
with Taq DNA polymerase Kit (Thermo Fisher Scientific)
and 800 nM of each forward and reverse oligonucleotide
(Table 1). Semi-quantitative PCR (qPCR) was performed
with the SYBR Fast q-PCR Kit (Kapa Biosystems, Cape
Town, South Africa) and 300 nM of each forward and re-
verse oligonucleotide (Table 1). The relative expression of
the target gene was normalized to the endogenous control
Hprt1, using the method 2-DDCt [26]. The products from
end-point, and in some cases, from semi-quantitative
PCR, were loaded onto 2% agarose gels containing
ethidium bromide, visualized under UV illumination and
photographed.
Immunofluorescence
Briefly, after permeabilization in a solution containing
PBS, 0.1% Triton X-100 and 1% BSA (Sigma-Aldrich),
cells were incubated with a primary antibody anti-GFP
raised in goat (1:500, Rockland, Houston, TX, USA),
followed by an incubation with a secondary antibody
conjugated to AlexaFluor® 555 (1:1000, Invitrogen,
Carlsbad, CA, USA). Slides were mounted with Prolong
Gold containing 4',6-diamidino-2-phenylindole (DAPI)
(Invitrogen). The number of GFP-positive colonies was
counted by epifluorescence microscopy and expressed as
transduction units (TU) per mL. Knee joint sections with
10 μm thickness were obtained in a cryostat and mounted
onto Superfrost slides (Thermo Fisher Scientific). After
permeabilization, the sections were incubated with a
primary antibody anti-GFP raised in rabbit (1:1000;
Invitrogen) overnight at 4 °C, and then processed as de-
scribed above. Images were acquired using a Zeiss LSM-
710 confocal microscope (Carl Zeiss MicroImaging,
GmbH, Jena, Germany).
In situ hybridization assays
In situ hybridization was conducted as described previously
[22]. Briefly, formalin-fixed paraffin-embedded tissue sec-
tions (4 μm) from knee joints were deparaffinized, rehy-
drated and treated with proteinase K (10 μg/mL for
10 min, room temperature). Sections were then incu-
bated for 16 h at 37 °C with hybridization buffer (30%
formamide, 50 mM Tris-HCl, 5 mM EDTA, 618 mM
NaCl, and 10% dextran sulfate) containing 200 nM of
locked nucleic acid (LNA)-modified antisense oligo-
nucleotide probes labelled with digoxigenin at their
3′- and 5′-ends (Exiqon, Vedbaek, Denmark). The anti-
sense probe targeting an exon–exon junction of the
Spag11c transcript sequence was 5′-TGGTCCAGGCT-
CATGGTAAGG-3′. A scrambled LNA probe was used as
a negative control. Sections were washed in series of
graded saline-sodium citrate buffer (SSC) solutions (5, 1,
and 0.2 × SSC) at 37 °C. Hybridized mRNA was detected
using sheep antibody anti-digoxigenin conjugated with
horseradish peroxidase (Roche, Indianapolis, IN, USA;
1:50 v/v) and peroxidase activity was revealed by 3,3′-
diaminobenzidine (DAB) reaction. Sections were coun-
terstained with Toluidine blue and mounted with
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Permount (Thermo Fisher Scientific). Slides were visu-
alized with a Nikon E800 microscope (Nikon, Melville,
NY, USA) and images acquired using a CoolSNAP-Pro
CCD digital camera and Image-Pro Express Software
(Media Cybernetics, Silver Spring, MD, USA).
Myeloperoxidase (MPO) activity
MPO activity was measured as an index of granulocyte
infiltration, as previously described [27]. Briefly, cell pel-
lets from knee joint lavages were homogenized in a po-
tassium phosphate-buffered (pH = 6) solution containing
0.5% hexadecyltrimethylammonium bromide. MPO ac-
tivity was measured in the presence of o-dianisidine
dihydrocholoride (Sigma-Aldrich) by optical density
readings at 450 nm in a FlexStation 3 microplate reader
(Molecular Devices, Sunnyvale, CA, USA). Sample re-
sults were interpolated into a linear regression generated
with a standard curve of MPO (0.05–0.8 U/mL; Sigma-
Aldrich). Data were expressed as units of MPO/mL.
Tryptase-like activity assay
Tryptase-like activity was measured in the super-
natant from knee joint lavages in the presence of
200 μM benzyloxycarbonyl-glycine-proline-arginine-7-
amino-4-methylcoumarin (Z-GPR-AMC) (Enzo Life
Sciences, GmbH, Lörrach, Germany) buffered in 50 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
and 120 mM NaCl (pH = 8.0) with 365/440 nm (excitation/
emission) in a Varioskan Flash microplate reader (Thermo
Fisher Scientific). Sample results were interpolated into a
linear regression generated with a standard curve of recom-
binant human tryptase-β1 (0.5–4.0 mU/mL; Promega).
Data was expressed as mU of tryptase-like activity per mL.
Cytokine and chemokine quantification
The concentration of IL-1β, -6, -17A and (C-X-C) ligand
(CXCL)1/KC in the supernatant of knee joint washes
was determined by using CBA Flex Kits, according to
the manufacturer’s instructions (BD, Franklin Lakes, NJ,
USA). Data were acquired in a FACSCanto II flow cyt-
ometer (BD) and analyzed with the program FCAP
Array v3.0 (Soft Flow Inc., Pecs, Hungary). Detection
limits for IL-1β, IL-6, IL-17A and CXCL1/KC were 4.32,
9.01, 8.72 and 10.48 pg/mL, respectively.
Statistical analysis
Data were analysed by using the software Prism version 6
(GraphPad Software, San Diego, CA, USA). Data compari-
son between the two groups was performed by unpaired
Student’s t test. The data from the histopathological scores
were analysed by Kruskal-Wallis and Dunn’s multiple
comparisons test. The time course of oedema formation
was analysed by two-way ANOVA and Tukey’s multiple
comparisons test. The remaining data was analysed by or-
dinary one-way ANOVA and Tukey’s multiple compari-
sons test. Data are expressed as mean ± SEM and values
of P < 0.05 were considered as statistically significant.
Results
The proteolytic balance is impaired in mBSA/IL-1β-induced
arthritis
Transcripts for Spag11c were constitutively expressed in
the knee joint from control mice, whereas transcripts for
Spag11a were not detected. On the other hand, both
transcripts were detected in positive control samples
prepared with RNA extracted from adult mice epididy-
mis (Fig. 1a). Additionally, the relative expression of
Spag11c did not change 7 days after induction of arth-
ritis (Fig. 1b). In situ hybridization revealed a positive
signal for Spag11c mRNA in chondrocytes of the hyaline
cartilage and in cells from the synovial membrane of the
knee joint from control (Fig. 1c and d) and mice submit-
ted to mBSA/IL-1β-induced arthritis (Fig. 1e and f). No
hybridization signal was detected in slices processed
with a negative control scrambled probe (Fig. 1g and h).
By qualitative analysis of knee joint sections stained with
Table 1 List of oligonucleotides
Gene symbol Strand Sequence (5’-3’) bp Accession number
SPAG11B/C Forward TGTTTCCAGGATCGTCTC 251 NM_058203
Reverse GCCTACTTGTGTTTCCAT
Spag11c Forward CTTACCACGAGCCTGAAC 139 NM_001039563
Reverse AACGGATGTAAGCAGCAG
Spag11a Forward ACAGAGAGCGAGCCGTAAAA 113 NM_153115
Reverse AGGCACACGGTGTTTCTGAT
Mcpt-6 Forward TGAGGCTTCTGAGAGTAA 403 NM_010781
Reverse GAGAGGCTCGTCATTATC
Hprt1 Forward TCCATTCCTATGACTGTAGA 90 NM_013556
Reverse ATCATCTCCACCAATAACTT
Gene symbols, oligonucleotide sequences, predicted base pair (bp) number for amplicons and NCBI accession numbers
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Toluidine blue, a few scattered mast cells were observed
in the synovia of control mice, whereas 7 days after in-
duction of arthritis, the number of mast cells seemed to
increase (Fig. 1h). Accordingly, the relative expression of
Mcpt-6 in the mouse knee joint increased up to twofold
7 days after induction of arthritis (Fig. 1i). Additionally,
tryptase-like activity was upregulated in the synovial
fluid from the knee joint of mice submitted to mBSA/
IL-1β-induced arthritis (Fig. 1j).
The lentivirus system promotes a stable heterologous
expression of hSPAG11B/C
The protocol for lentivirus production presented in this
study provided consistent titers ranging from 1.1 × 109
up to 2.0 × 1010 TU/mL. We then evaluated if transgene
expression was still detected in the knee joint up to
7 days after induction of inflammatory arthritis. Indeed,
the SPAG11B/C transcript was detected in knee joint
samples from mice previously injected with the corre-
sponding lentivirus phSPAG11B/C (Fig. 2a). Additionally,
immunofluorescence studies demonstrated that the
transgene integration occurred predominantly in synovio-
cytes, since GFP-positive cells were restricted to the syn-
ovial membrane (Fig. 2b and c), while no positive cells
were observed in the cartilage (Fig. 2d).
Lentivirus-mediated heterologous expression of
hSPAG11B/C or treatment with APC366 re-establishes the
proteolytic balance
The Mcpt-6 transcript level and tryptase-like activity in
the synovial fluid were both increased in the mouse knee
joint 7 days after the induction of arthritis (Fig. 3). The
intra-articular injection of the tryptase inhibitor APC366
(10–100 μM) or the transduction of knee joints with
phSPAG11B/C reduced the tryptase-like activity in ani-
mals with arthritis. In contrast, transduction with the
control lentivirus pWPXLd-IG or injection with vehicle
had no effect (Fig. 3a and b). Neither APC366 nor trans-
duction with phSPAG11B/C, however, reverted the in-
crease of Mcpt-6 gene expression observed 7 days after
induction of arthritis (Fig. 3c and d).
Fig. 1 The proteolytic balance is impaired in mBSA/IL-1β-induced arthritis. a. Analytical agarose gel electrophoresis of RT-qPCR products for
Spag11c and Spag11a mRNA in knee joints from control or arthritis mice. Hrpt1 was used as an endogenous control. Adult mouse epididymis
cDNA was used as positive control for Spag11c and Spag11a mRNA amplification. b. RT-qPCR analysis of Spag11c relative expression in control
and arthritis mouse knee joints. N = 6 mice per group. c-h. In situ hybridization with Spag11c or scrambled digoxigenin-labelled LNA probes in
knee joint sections from control and arthritis mice. Hybridization signal was detected in chondrocytes within the hyaline cartilage from control
and arthritis mice (c and e) and in cells from the synovial membrane (d and f). No staining was observed in negative control assays with scrambled
digoxigenin-labelled LNA probe, neither in hyaline cartilage (g) nor in the synovial membrane (h). Right bottom insets represent magnifications of the
respective square-demarked areas. The arrowheads indicate the normal synovial lining in control animals. The arrows evidence the presence of several
mast cells in arthritis mice. Images are representative of five mice per group. i. RT-qPCR analysis of Mcpt-6 relative expression in control and arthritis
mouse knee joints. N = 11–12 mice per group. j. Measurement of tryptase-like activity in the synovial fluid from knee joints of control and arthritis mice.
N = 13–15 mice per group. Abbreviation: n.s. not significant
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Lentivirus-mediated heterologous expression of
hSPAG11B/C or treatment with APC366 has marginal
impact on mBSA/IL-β-induced arthritis
Animals submitted to mBSA/IL-1β-induced arthritis
presented a long-lasting and biphasic oedema, which
peaked on days 1 and 7. The intra-articular treatment
with APC366 (10–100 μM) reduced the late phase of
oedema formation, 7 days after the induction of arthritis
(Fig. 4a). Similarly, animals with arthritis previously
transduced with phSPAG11B/C, but not with pWPXLd-
IG, presented reduced oedema at day 7 (Fig. 4b).
Histopathological analysis evidenced that while knee
joints from control animals presented no signs of joint
inflammation (Fig. 4c), mBSA/IL-1β-treated mice devel-
oped a severe arthritis 7 days after its induction, with an
intense influx of leukocytes to the knee joint cavity and
synovial membrane (synovitis), pannus formation, sub-
chondral bone erosion (Fig. 4d) and degradation of the
extracellular matrix of hyaline cartilage (Additional file 1).
Similarly, animals previously transduced with pWPXLd-
IG developed severe arthritis (Fig. 4e). The knee joints of
mice transduced with phSPAG11B/C presented a trend
for a lower degree of inflammatory arthritis, particularly
regarding synovitis and joint cavity exudate (Fig. 4f).
Although none of the histopathological parameters was
significantly reduced in comparison to animals sub-
mitted to mBSA/IL-1β-induced arthritis, either pre-
injected with vehicle or transduced with the control
lentivirus pWPXLd-IG (Fig. 4g).
MPO activity, a biochemical index of granulocyte infil-
tration, increased in the joint cavity exudate 7 days after
induction of arthritis, when compared to control ani-
mals. The treatment of animals with APC366 or the
transduction with phSPAG11B/C had no major effect on
the increased MPO activity (Fig. 5a and b).
Lentivirus-mediated heterologous expression of
hSPAG11B/C or treatment with APC366 inhibits the
production of inflammatory mediators
The release of IL-6 and CXCL1/KC to the synovial fluid
increased 7 days after induction of arthritis, albeit
CXCL1/KC concentration was just slightly above the de-
tection limit (Fig. 6). This increase of IL-6 associated to
mBSA/IL-1β-induced arthritis was dose-dependently re-
duced by the treatment with APC366 (Fig. 6a), or the
previous transduction with phSPAG11B/C (Fig. 6b). The
Fig. 2 The lentivirus system promoted a stable heterologous expression of hSPAG11B/C. a. Representative agarose-gel electrophoresis of end-
point RT-PCR for SPAG11B/C in knee joints transduced with pWPXLd-IG or phSPAG11B/C from animals killed 7 days after induction of arthritis. The
lentivirus vector phSPAG11B/C (1 × 103 copies) was used as DNA template for the indicated positive control (+ control). Hrpt1 was used as an
endogenous control. b-d. Representative confocal photomicrographs of GFP immunoreactivity (pseudocolored in green) performed in knee joints,
evidencing the synovial membrane from a mouse transduced with 1 × 107 TU/joint of phSPAG11B (b), the synovial membrane of a mouse not
transduced with lentivirus (c) and the hyaline cartilage from a mouse transduced with 1 × 107 TU/joint of phSPAG11B (d). The dashed line encircles the
inner boundaries of the synovia and the arrowheads indicate the lining layer of the synovial membrane. Abbreviations: JC joint cavity, HC hyaline cartilage
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control lentivirus pWPXLd-IG had no effect on IL-6 re-
lease. Similarly, the production of CXCL1/KC was re-
duced by the treatment with APC366 (Fig. 6c), or the
previous transduction with phSPAG11B/C (Fig. 6d).
However, the transduction with pWPXLd-IG also re-
duced the production of CXCL1/KC. Neither IL-1β nor
IL-17A was detected in any of the experimental condi-
tions tested.
Discussion
Previous studies have shown that rheumatoid arthritis
and experimental models of this disease are associated
with an intense mastocytosis and mast cell degranulation
in affected joints, suggesting that an increased release of
active tryptase occurs in this disease [2–4, 12]. Since
proteolytic activity can be counterbalanced by the release
of endogenous inhibitors, we initially evaluated if an actual
increased proteolytic activity due to an unbalance between
mast cell-restricted tryptase and endogenous inhibitors
takes place during joint inflammation. Indeed, this hy-
pothesis was supported by our results, wherein Mcpt-6
gene expression as well as tryptase-like activity were up-
regulated 7 days after mBSA/IL-1β-induced arthritis to
levels seemingly not counterbalanced by endogenous tryp-
tase inhibitors, such as SPAG11B/C. However, in animals
subjected to lentivirus-mediated heterologous expression
of SPAG11B/C, as well as to the treatment with APC366,
the proteolytic balance was re-established to a signifi-
cant extent, since both strategies inhibited the increase
of tryptase-like activity in the synovial fluid, 7 days after
induction of arthritis. In contrast, neither the recom-
binant expression of SPAG11B/C nor the treatment
with APC366 impacted the upregulation of Mcpt-6
gene expression, thus indicating that the reduced
tryptase-like activity was due to enzymatic inhibition.
Hence, in view of the upregulated tryptase-like activity,
Fig. 3 Effect of lentivirus-mediated heterologous expression of hSPAG11B/C or APC366 on proteolytic balance. a and b. Effect of the synthetic
tryptase inhibitor APC366 (10–100 μM) or the transduction with the lentiviruses phSPAG11B/C or pWPXLd-IG, as control, in the tryptase-like activity in
the synovial fluid of mouse knee joints 7 days after the induction of arthritis. ***P < 0.001 vs. control group; #P < 0.05; ##P < 0.01 vs. arthritis groups;
n = 6–8 per group). c and d. Relative expression of Mcpt-6 in the mouse knee joint 7 days after induction of arthritis in animals treated
with APC366 or transduced with phSPAG11B/C or pWPXLd-IG. *P < 0.05; **P < 0.01; ***P < 0.001 vs. control groups (n = 5–6 per group).
Abbreviation: n.s. not significant
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we investigated whether the re-establishment of the
proteolytic balance by tryptase inhibition would be
beneficial.
Initially, we assessed the feasibility of using a lentivirus-
mediated expression system to promote the stable expres-
sion of the β-defensin SPAG11B/C in synovial joints. It is
worthwhile mentioning that the protocol for lentivirus
production presented herein yielded the production of
constant high titers of functional lentiviral particles. Like-
wise, in transduced animals, both GFP and SPAG11B/C
were still detected 14 days after mice knee joint
transduction, indicating a stable expression of transgenes,
even after the induction of arthritis, wherein an extensive
hyperplasia of fibroblast-like synoviocytes occurred. Addi-
tionally, GFP-positive cells were restricted to the synovial
membrane, whereas no positive cell was observed in
chondrocytes, in accordance with previous studies using
VSV-G pseudotyped HIV-1 derived lentivirus in knee
joints of rodents [28, 29]. Furthermore, a previous study
reported the occurrence of only negligible levels of trans-
duction of off-target organs after an intra-articular injec-
tion of lentiviral particles in synovial joints [28]. As a
Fig. 4 Effect of lentivirus-mediated heterologous expression of hSPAG11B/C and APC366 in mBSA/IL-β-induced arthritis. a and b. Time course of
oedema formation (increase in knee joint medio-lateral diameter) after induction of arthritis with mBSA/IL-1β in animals treated with the synthetic
tryptase inhibitor APC366 at 10–100 μM (N = 6–8 mice per group), or previously transduced with pWPXLd-IG or phSPAG11B/C (N = 13–14 mice
per group). ***P < 0.001, arthritis + vehicle groups vs. control; @@P < 0.01; @@@P < 0.001, arthritis + APC366 (10 μM) or arthritis + pWPXLd-IG groups vs.
control; &&&P < 0.001, arthritis + APC366 (100 μM) or arthritis + phSPAG11B/C groups vs. control; #P < 0.05; ###P < 0.001, arthritis + APC366 (100 μM) or
arthritis + phSPAG11B/C groups vs. arthritis + vehicle. c-f. Representative light photomicrographs of knee joint slices stained by the method of eosin
and haematoxylin from a control animal (c), or animals submitted to mBSA/IL-1β-induced arthritis, previously injected with vehicle (d), or transduced
with 2 × 106 TU/joint of pWPXLD-IG (e) or phSPAG11B/C (f). The arrows indicate areas of intense synovitis. The arrowheads show areas with moderate
synovitis. g. Total and individual histopathological scores of inflammatory parameters (N = 4–6 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001, vs.
control group. Abbreviations: JC joint cavity, SM synovial membrane, Ctrl control, n.s. not significant
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Fig. 5 Effect of lentivirus-mediated heterologous expression of hSPAG11B/C and APC366 on MPO activity. a and b. MPO activity in the synovial
fluid of knee joint 7 days after induction of arthritis in animals treated with APC366 at 10–100 μM (N= 6–8 mice per group) or previously transduced
with pWPXLd-IG or phSPAG11B/C (N = 14–15 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001 vs. control groups. Abbreviation: n.s. not significant
Fig. 6 Effect of lentivirus-mediated heterologous expression of hSPAG11B/C and APC366 on cytokines and chemokine production. a and b. Effect
of the synthetic tryptase inhibitor APC366 (10–100 μM) or the knee joint transduction (1 × 107 TU/joint) with phSPAG11B/C in the release of IL-6
(a and b) and CXCL1/KC (c and d) 7 days after the induction of arthritis with mBSA/IL-1β. (N = 6 mice per group). *P < 0.05; **P < 0.01; ***P < 0.001
vs. control groups; #P < 0.05; ##P < 0.01; ###P < 0.001 vs. arthritis + vehicle groups. Abbreviation: n.s. not significant
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whole, this indicates that lentivirus-based gene delivery is
an instrumental tool to study the relevance of target genes
in synovial joint physiology and disease.
We then screened the anti-inflammatory potential of
SPAG11B/C isoform by using the lentivirus-mediated
expression system, in parallel to the treatment with the
synthetic tryptase inhibitor APC366. Mast cell-restricted
tryptases are well-established oedematogenic mediators,
by a mechanism involving activation of PAR2 receptors
[30–32]. For instance, an intra-articular injection of syn-
thetic hexapeptides corresponding to the tethered ligand
sequence revealed after PAR2 cleavage by trypsin-like
serine proteases, such as tryptase, induced swelling in syn-
ovial joints from normal rats [33–35]. Besides, a recent
study shown that an intra-articular injection of mast cell
tryptase into the mouse knee joint induces hyperaemia,
oedema and pain [36]. This suggests that an oedemato-
genic pathway triggered by PAR2 activation is ready to
take place in normal tissue conditions. Herein, both strat-
egies of tryptase inhibition reduced oedema formation,
but only in the late phase of mBSA/IL-1β-induced arth-
ritis, thus indicating that mast cell accumulation and/or
Mcpt-6 upregulation occur late in this model. Accordingly,
the relative level of Mcpt-6 mRNA was upregulated 7 days
after induction of arthritis. As a whole, while previous
studies developed by us and others have shown that PAR2
pro-inflammatory and nociceptive signalling pathways are
ready to be pharmacologically triggered even in synovial
joints from healthy animals, the present study indicates
that its endogenous proteolytic activator (i.e. mast cell-
restricted tryptase), only becomes quantitatively relevant
on the late phase of mBSA/IL-1β-induced arthritis.
Earlier studies based on mast cell-depleted mice due
to c-kit signalling deficiency reported a central role of
these cells in neutrophil infiltration and joint degener-
ation [5–7]. Later on it was shown that c-kit deficiency
was associated with important hematopoietic impair-
ments, including a high degree of neutropenia, indicat-
ing that the resistance of these mice to experimental
arthritis was mostly associated to this hematopoietic dis-
order [37], since neutrophils are pivotal cellular effectors
in joint degeneration [38]. Considering that mast cells
produce a large repertoire of inflammatory mediators,
the role of tryptase in experimental arthritis was investi-
gated in mice lacking Mcpt-6 and -7. This study reported
a reduced neutrophil infiltration and joint degeneration
associated to mBSA/IL-1β-induced arthritis [12]. Later
on, the same group demonstrated that the in vitro
stimulation of mouse or human fibroblast-like synovio-
cytes with tryptase upregulated the expression of the
neutrophil chemokines CXCL1/KC, CXCL5/LIX and
CXCL8/IL-8 [13, 39]. Similarly, our study demonstrated
that the concentration of CXCL1/KC in the knee joint
synovial fluid was reduced after tryptase inhibition.
In view of the findings reported with Mcpt-6 and -7
knockout mice [12, 13], we then assessed whether tryptase
inhibition would suffice to impact neutrophil infiltration
and joint degeneration. As revealed by histopathological
analysis, animals submitted to mBSA/IL-1β-induced arth-
ritis, either pre-injected with vehicle or transduced with the
control lentivirus pWPXLd-IG, developed a severe inflam-
matory arthritis, notably with an intense infiltration of leu-
kocytes within the joint cavity and synovial membrane.
Surprisingly, although the transduction with phSPAG11B/C
or the treatment with APC366 clearly inhibited tryptase-
like activity by a significant extent, both inhibitory strategies
had only marginal, if any effect on neutrophil infiltration, as
depicted by histopathological analysis and MPO activity.
This suggests that residual tryptase activity over the base-
line level may be sufficient to support neutrophil influx, by
a mechanism yet to be identified, but seemingly independ-
ent of CXCL1/KC, since the concentration level of this che-
mokine barely surpassed the detection limits 7 days after
the induction of arthritis.
The production of IL-6 is increased in RA [40] and its
signalling plays a central role in joint inflammation and
degeneration [41]. Indeed, studies with monoclonal anti-
bodies designed to target IL-6 receptors (IL-6R) reported
an attenuation of collagen-induced arthritis in mice [42],
as well as in human RA [43]. In our study, IL-6 produc-
tion was upregulated in the synovial fluid of mice 7 days
after induction of arthritis. Additionally, IL-6 overpro-
duction was consistently reversed by the recombinant
expression of SPAG11B/C or the treatment with APC366.
Similarly, a recent study based on collagen-induced arth-
ritis reported a reduction of IL-6 serum levels in mast
cell-deficient mice [9]. In this way, our data clearly indi-
cates that tryptase must be the major mast cell mediator
regulating IL-6 production in arthritis. Intriguingly, while
some inflammatory parameters associated to mBSA/IL-
1β-induced arthritis were attenuated by both strategies of
tryptase inhibition, the degenerative parameters investi-
gated were not affected. Similarly, a previous study
demonstrated that IL-6 knockout mice were only mildly
protected from mBSA/IL-1β-induced arthritis [44]. This
dichotomy seems to be due to the fact that while IL-6
exert pro-inflammatory actions through activation of sol-
uble IL-6 receptors (sIL-6R), the activation of membrane-
bound IL-6 receptors (mIL-6R) is rather protective [41].
In this way, while sIL-6R blockade is beneficial, the global
inhibition of IL-6 seems to be detrimental. This may ex-
plain the limited anti-inflammatory effect of tryptase in-
hibition on mBSA/IL-1β-induced arthritis observed in the
present study.
Conclusions
Our study demonstrated that the lentivirus-mediated
heterologous expression of an endogenous tryptase
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inhibitor (hSPAG11B/C) as well as the intra-articular
administration of APC366 presented closely overlap-
ping inhibitory effects on tryptase-like activity, oedema
formation, IL-6 and CXCL1/KC production, whereas
leukocyte infiltration, cartilage degradation and sub-
chondral bone erosion were not affected. These results
show that tryptase-β inhibition offers limited effect on
mBSA/IL-β-induced arthritis, thus suggesting that the
therapeutic application of these inhibitors to rheuma-
toid arthritis would be restrained to palliative care, but
not as disease-modifying drugs, unless the development
of far more potent molecules in the future uncovers a
broader potential, as previously highlighted by studies
based on transgenic animals. Furthermore, clinical rele-
vance may also lay in their potential effectiveness as RA
adjuvant therapy if associated with drugs encompassing
other inflammatory pathways implicated in the patho-
physiology of this disease, a topic that will require
future investigation.
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